Ariela Mota Ferreira

Ariela Mota Ferreira

Auto-generated profile, based on publicly available information

Ariela Mota Ferreira

Universidade Estadual de Montes Claros, Brasil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
CCClareci Cardoso
Clareci Cardoso
ARAntonio Luiz P. Ribeiro
Antonio Luiz P. Ribeiro
COClaudia Di Lorenzo Oliveira
Claudia Di Lorenzo Oliveira
LOLea Campos Oliveira
Lea Campos Oliveira
AFAriela Mota Ferreira
Ariela Mota Ferreira
ESEster Cerdeira Sabino
Ester Cerdeira Sabino
The effectiveness of anti-parasite treatment with benznidazole in the chronic Chagas disease (ChD) remains uncertain. We evaluated, using data from the NIH-sponsored SaMi-Trop prospective cohort study, if previous treatment with benznidazole is associated with lower mortality, less advanced cardiac disease and lower parasitemia in patients with chronic ChD. The study enrolled 1,959 ChD patients and abnormal electrocardiogram (ECG) from in 21 remote towns in Brazil. A total of 1,813 patients were evaluated at baseline and after two years of follow-up. Those who received at least one course of benznidazole were classified as treated group (TrG = 493) and those who were never treated as control group (CG = 1,320). The primary outcome was death after two-year follow-up; the secondary outcomes were presence at the baseline of major ChD-associated ECG abnormalities, NT-ProBNP levels suggestive of heart failure, and PCR positivity. Mortality after two years was 6.3%; it was lower in the TrG (2.8%) than the CG (7.6%); adjusted OR: 0.37 (95%CI: 0.21;0.63). The ECG abnormalities typical for ChD and high age-adjusted NT-ProBNP levels suggestive of heart failure were lower in the TrG than the CG, OR: 0.35 [CI: 0.23;0.53]. The TrG had significantly lower rates of PCR positivity, OR: 0.35 [CI: 0.27;0.45]. Patients previously treated with benznidazole had significantly reduced parasitemia, a lower prevalence of markers of severe cardiomyopathy, and lower mortality after two years of follow-up. If used in the early phases, benznidazole treatment may improve clinical and parasitological outcomes in patients with chronic ChD. ClinicalTrials.gov, Trial registration: NCT02646943. Chagas disease remains as one of the most neglected infectious diseases of the world, with millions of persons infected and dozens of thousands of deaths every year. The disease has a very long natural history and few options of etiologic treatment, including antiparasitic [1] drugs benznidazole and nifurtimox. Benznidazole has been recommended for treatment of the disease based mostly in physiopathological assumptions and relatively small observational studies and, recently, a negative trial was published, showing the absence of benefit of benznidazole in patients with Chagas cardiopathy. Thus, there is an urgent need not only of new therapeutic options but also of further evidence of the utility of benznidazole, at least in those patients with less severe disease. We conducted an observational study in the NIH SaMi-Trop cohort comparing patients with self-reported previous treatment with benznidazole with non-treated ones, using as primary outcome death in the follow-up of 2 years, and as secondary outcomes markers of severity based in the ECG and NT-proBNP levels, as well as parasitemia by PCR for Trypanosoma cruzi DNA in blood. Patients previously treated with benznidazole had significantly reduced parasitemia, a lower frequency of markers of severe cardiomyopathy and reduced mortality. If used in the early phases of Chagas disease, benznidazole treatment may result in better clinical and parasitological outcomes. It is reasonable to consider treating all Chagas disease patients without advanced cardiopathy with benznidazole, especially those less than 50 years-old of age.

9 February 2018 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MZMaan Zrein
Maan Zrein
EGElodie Granjon
Elodie Granjon
LGLucie Gueyffier
Lucie Gueyffier
JCJulie Caillaudeau
Julie Caillaudeau
PLPeter Liehl
Peter Liehl
ESEster Cerdeira Sabino
Ester Cerdeira Sabino
Trypanosoma cruzi parasite, the causative agent of Chagas disease, infects about six million individuals in more than 20 countries. Monitoring parasite persistence in infected individuals is of utmost importance to develop and evaluate treatments to control the disease. Routine screening for infected human individuals is achieved by serological assays; PCR testing to monitor spontaneous or therapy-induced parasitological cure has limitations due to the low and fluctuating parasitic load in circulating blood. The aim of the present study is to evaluate a newly developed antibody profiling assay as an indirect method to assess parasite persistence based on waning of antibodies following spontaneous or therapy-induced clearance of the infection. We designed a multiplex serology assay, an array of fifteen optimized T. cruzi antigens, to evaluate antibody diversity in 1654 serum samples from chronic Chagas patients. One specific antibody response (antibody 3, Ab3) showed a strong correlation with T. cruzi parasite persistence as determined by T. cruzi PCR positive results. High and sustained Ab3 signal was strongly associated with PCR positivity in untreated patients, whereas significant decline in Ab3 signals was observed in BZN-treated patients who cleared parasitemia based on blood PCR results. Ab3 is a new surrogate biomarker that strongly correlates with parasite persistence in chronic and benznidazole-treated Chagas patients. We hypothesize that Ab3 is induced and maintained by incessant stimulation of the immune system by tissue-based and shed parasites that are not consistently detectable by blood based PCR techniques. Hence, a simple immunoassay measurement of Ab3 could be beneficial for monitoring the infectious status of seropositive patients. Chagas disease is a zoonosis caused by Trypanosoma cruzi infection. In this study, we sought to identify a simple serologic biomarker that can supersede PCR techniques in characterizing patients for parasite persistence, whether circulating or shielding in tissues. A multiparametric assay was designed to evaluate antibody diversity in untreated and benznidazole-treated chronic cardiomyopathy patients. Out of 15 different antigens we identified a distinct antibody specificity that strongly correlates with parasite persistence. This putative biomarker could be used to monitor active infection in T. cruzi seropositive patients and identify patients that responded to anti-parasitic therapy.

6 December 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
BBBruno Oliveira de Figueiredo Brito
Bruno Oliveira de Figueiredo Brito
ZAZachi I. Attia
Zachi I. Attia
LMLarissa Natany A. Martins
Larissa Natany A. Martins
PPPablo Perel
Pablo Perel
MNMaria Carmo P. Nunes
Maria Carmo P. Nunes
FLFrancisco Lope-Jimenez
Francisco Lope-Jimenez
Left ventricular systolic dysfunction (LVSD) in Chagas disease (ChD) is relatively common and its treatment using low-cost drugs can improve symptoms and reduce mortality. Recently, an artificial intelligence (AI)-enabled ECG algorithm showed excellent accuracy to detect LVSD in a general population, but its accuracy in ChD has not been tested. To analyze the ability of AI to recognize LVSD in patients with ChD, defined as a left ventricular ejection fraction determined by the Echocardiogram ≤ 40%. This is a cross-sectional study of ECG obtained from a large cohort of patients with ChD named São Paulo-Minas Gerais Tropical Medicine Research Center (SaMi-Trop) Study. The digital ECGs of the participants were submitted to the analysis of the trained machine to detect LVSD. The diagnostic performance of the AI-enabled ECG to detect LVSD was tested using an echocardiogram as the gold standard to detect LVSD, defined as an ejection fraction <40%. The model was enriched with NT-proBNP plasma levels, male sex, and QRS ≥ 120ms. Among the 1,304 participants of this study, 67% were women, median age of 60; there were 93 (7.1%) individuals with LVSD. Most patients had major ECG abnormalities (59.5%). The AI algorithm identified LVSD among ChD patients with an odds ratio of 63.3 (95% CI 32.3–128.9), a sensitivity of 73%, a specificity of 83%, an overall accuracy of 83%, and a negative predictive value of 97%; the AUC was 0.839. The model adjusted for the male sex and QRS ≥ 120ms improved the AUC to 0.859. The model adjusted for the male sex and elevated NT-proBNP had a higher accuracy of 0.89 and an AUC of 0.874. The AI analysis of the ECG of Chagas disease patients can be transformed into a powerful tool for the recognition of LVSD. Chagas disease (ChD) is caused by the protozoan parasite Trypanosoma cruzi and continues to be a health problem despite the control of its transmission. ChD is a heterogeneous condition with a wide variation in its clinical course and prognosis. The majority (60%–70%) of infected individuals remain asymptomatic throughout life. Although some develop only conduction defects and mild segmental wall motion abnormalities, others develop severe symptoms of heart failure (HF), thromboembolic phenomena, and life threatening ventricular arrhythmias. HF is one of major causes of the death of patients with ChD. There is some evidence on effective drugs against the parasite in the chronic form of the disease capable of preventing long-term adverse outcomes, but it is still limited. However low-cost medications are able to reduce mortality and improve the quality of life of patients with HF. Because of the lack of tertiary care facilities outside urban centers, an automatic diagnostic tool based on the ECG, which is a relatively simple exam without requiring human interpretation, would improve the capacity to recognize HF. Recently, digital signals of the electrocardiogram were recognized by Artificial Intelligence (AI) and associated with an excellent accuracy for HF in the general population. Our results demonstrate that AI-ECG could ensure a rapid recognition of HF in patients who require a referral to a cardiologist and the use of disease-modifying drugs. AI can be used as a powerful public heath tool, it can transform the lives of 6 million patients with ChD worldwide, and it may well have a formidable impact on patient management and prognosis.

29 June 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
AFAriela Mota Ferreira
Ariela Mota Ferreira
ÉSÉster Cerdeira Sabino
Éster Cerdeira Sabino
LOLea Campos de Oliveira
Lea Campos de Oliveira
COCláudia Di Lorenzo Oliveira
Cláudia Di Lorenzo Oliveira
CCClareci Silva Cardoso
Clareci Silva Cardoso
DHDesirée Sant’ Ana Haikal
Desirée Sant’ Ana Haikal
The present study aims to investigate how the social context contributes to the prognosis of Chagas disease (CD). This is a multilevel study that considered individual and contextual data. Individual data came from a Brazilian cohort study that followed 1,637 patients who lived in 21 municipalities to which CD is endemic, over two years. Contextual data were collected from official Brazilian government databases. The dependent variable was the occurrence of cardiovascular events in CD during the two-year follow-up, defined from the grouping of three possible combined events: death, development of atrial fibrillation, or pacemaker implantation. Analysis was performed using multilevel binary logistic regression. Among the individuals evaluated, 205 (12.5%) manifested cardiovascular events in CD during two years of follow-up. Individuals living in municipalities with a larger rural population had protection for these events (OR = 0.5; 95% CI = 0.4–0.7), while those residing in municipalities with fewer physicians per thousand inhabitants (OR = 1.6; 95% CI = 1.2–2.5) and those living in municipalities with lower Primary Health Care (PHC) coverage (OR = 1.4; 95% CI = 1.1–2.1) had higher chances of experiencing cardiovascular events. Among the individual variables, the probability of experiencing cardiovascular events was higher for individuals aged over 60 years (OR = 1.4; 95% CI = 1.01–2.2), with no stable relationship (OR = 1.4; 95% CI = 0.98–2.1), without previous treatment with Benznidazole (OR = 1.5; 95% CI = 0.98–2.9), with functional class limitation (OR = 2.0; 95% CI = 1.4–2.9), with a QRS complex duration longer than 120 ms (OR = 1.5; 95% CI = 1.1–2.3), and in individuals with high NT-proBNP levels (OR = 6.4; 95% CI = 4.3–9.6). CONCLUSION: The present study showed that the occurrence of cardiovascular events in individuals with CD is determined by individual conditions that express the severity of cardiovascular involvement. However, these individual characteristics are not isolated protagonists of this outcome, and the context in which individuals live, are also determining factors for a worse clinical prognosis. Chagas disease (CD) is a serious public health problem in Latin America and has a strong social impact worldwide. Up to 30% of the infected people may have cardiac alterations, which are associated with a worse prognosis and with high mortality rates. The occurrence of CD is associated with contexts of social vulnerability. However, no studies have been identified that assessed whether unfavorable social contexts are related to the prognosis and evolution of CD, which is the purpose of our study. We evaluated 1,637 patients with CD who lived in 21 municipalities located in regions to which CD is endemic in Brazil, over a two-year period. Of these people, 12.5% ​​evolved into a worse prognosis. Our study revealed that socio-demographic and clinical characteristics of individuals were not isolated protagonists of the evolution of CD. The context in which individuals lived was also a determining factor of a worse prognosis, including living in municipalities with a smaller rural population, fewer physicians, and a smaller Primary Health Care (PHC) coverage. Thus, we observed that characteristics related to the health care available in the municipalities influenced the evolution of CD. This knowledge has the potential to support health care planning that is more appropriate for the evolution of patients with CD, especially considering poor and remote regions.

1 January 2021 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
COClaudia Di Lorenzo Oliveira
Claudia Di Lorenzo Oliveira
CCClareci Cardoso
Clareci Cardoso
NBNayara Ragi Baldoni
Nayara Ragi Baldoni
LNLarissa Natany
Larissa Natany
AFAriela Mota Ferreira
Ariela Mota Ferreira
ESEster Cerdeira Sabino
Ester Cerdeira Sabino
The SaMi-Trop project is a cohort study conducted in 21 municipalities of endemic areas of Chagas disease, including 1,959 patients with chronic Chagas cardiomyopathy. In this article we updated the results of the project, adding information from the second cohort visit. Trypanosoma cruzi-seropositive patients were enrolled from the primary care Telehealth service in Minas Gerais State, Brazil. The eligibility criterium for the second visit was the participation in the baseline evaluation. Of 1,959 participants at the baseline assessment, 1,585 (79.9%) returned after two years for the second evaluation. The mortality rate was 6.7%, but varied from 0.9% to 18.2% when it was stratified by certain clinical characteristics. A lower age-adjusted NT-Pro-BNP level (less than 300) and a prior benznidazole treatment were associated with lower mortality. There was an improvement in most quality of life domain scores. Participants have also reported fewer signs and symptoms and greater use of medication. The second follow-up visit will be complete in Oct 2021.

3 January 2024 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
NBNayara Ragi Baldoni
Nayara Ragi Baldoni
LSLea Campos de Oliveira-Da Silva
Lea Campos de Oliveira-Da Silva
AGAna Carolina Oliveira Gonçalves
Ana Carolina Oliveira Gonçalves
NQNayara Dornela Quintino
Nayara Dornela Quintino
AFAriela Mota Ferreira
Ariela Mota Ferreira
CCClareci Cardoso
Clareci Cardoso
: The aims of this study were to estimate the prevalence of gastrointestinal manifestations among individuals with positive serology for Chagas disease (ChD) and to describe the clinical gastrointestinal manifestations of the disease. A systematic review with meta-analysis was conducted based on the criteria and recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The PubMed, Scopus, Virtual Health Library, Web of Science, and Embase databases were used to search for evidence. Two reviewers independently selected eligible articles and extracted data. RStudio® software was used for the meta-analysis. For subgroup analysis, the studies were divided according to the origin of the individuals included: 1) individuals from health units were included in the health care service prevalence analysis, and 2) individuals from the general population were included in the population prevalence analysis. A total of 2,570 articles were identified, but after removal of duplicates and application of inclusion criteria, 24 articles were included and 21 were part of the meta-analysis. Most of the studies were conducted in Brazil. Radiological diagnosis was the most frequent method used to identify the gastrointestinal clinical form. The combined effect of meta-analysis studies showed a prevalence of gastrointestinal manifestations in individuals with ChD of 12% (95% CI, 8.0–17.0%). In subgroup analysis, the prevalence for studies involving health care services was 16% (95% CI, 11.0–23.0%), while the prevalence for population-based studies was 9% (95% CI, 5.0–15.0%). Megaesophagus and megacolon were the main forms of ChD presentation in the gastrointestinal form. The prevalence of gastrointestinal manifestations of ChD was 12%. Knowing the prevalence of ChD in its gastrointestinal form is an important step in planning health actions for these patients.